Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

NCT05090904 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT05090904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05090904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Lead sponsor
Insmed Incorporated
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2021
Completion date
November 1, 2022
Enrollment
29 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis